Partial AUCs in Long-Acting Injectables: Rationale, Challenges, Variability, Usefulness, and Clinical Relevance

Area of Science:

• Pharmacokinetics and Drug Development
• Bioequivalence Studies
• Formulation Science

Background:

• Bioequivalence assessments commonly rely on area under the curve (AUC) and maximum concentration (Cmax).
• Partial AUCs (pAUCs) are proposed to capture formulation differences not evident with AUC and Cmax alone.
• Challenges exist in defining appropriate pAUC cut-off points, particularly for complex drug products.

Purpose of the Study:

• To evaluate the utility and challenges of using partial AUCs (pAUCs) in bioequivalence studies for generic long-acting injectable (LAI) products.
• To analyze the impact of pAUC estimation on identifying formulation differences within the dosing interval.
• To examine regulatory perspectives from the FDA and EMA regarding pAUC application in LAI development.

Main Methods:

• Review of six case studies involving generic LAI product development.
• Analysis of pharmacokinetic (PK) data, including AUC, Cmax, and pAUCs.
• Evaluation against regulatory guidelines from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA).

Main Results:

• pAUCs can offer additional insights into bioequivalence beyond traditional AUC and Cmax, especially for LAIs.
• Determining clinically relevant and statistically robust pAUC cut-off points remains a significant challenge.
• Variability in pAUC estimates can be influenced by the choice of cut-off points and complex PK profiles of LAIs.

Conclusions:

• Partial AUCs (pAUCs) show potential as supplementary metrics for assessing bioequivalence in generic long-acting injectables (LAIs).
• The selection of appropriate pAUC cut-off points is critical and requires careful consideration of product-specific PK/PD relationships and regulatory expectations.
• Further research and consensus are needed to standardize pAUC methodologies for LAI bioequivalence evaluations.